Download Files:
FHD-609
$450 – $3,600
Products Details
Product Description
– FHD-609 is an inhibitor and a degrader of BRD9 (bromodomain-containing protein 9). FHD-609 targets to ncBAF, can be used for research of wide range of cancers that contain a mutation in a BAF complex subunit. FHD-609 in combination with Telomelysin or INO5401, may play a role in adrenocortical carcinoma (ACC) treatment[1][2].
Web ID
– HY-153367
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C47H56N8O6
References
– [1]Rechberger JS, et al. Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets. Expert Opin Ther Targets. 2022 Mar;26(3):187-192. |[2]Hescheler DA, et al. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. Cancers (Basel). 2022 May 31;14(11):2721.
CAS Number
– 2676211-64-4
Molecular Weight
– 829.00
Compound Purity
– 99.15
SMILES
– COC1=C(CN2CCC(CN3CCC4(CN(C5=CC(C(N([C@]6([H])C(NC(CC6)=O)=O)C7)=O)=C7C=C5)C4)CC3)CC2)C(OC)=CC(C(C8=C9C=NC(N%10CCC%10)=C8)=CN(C)C9=O)=C1
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– Epigenetic Reader Domain
Isoform
– BRD9
Pathway
– Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
